WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H581557
CAS#: 16809-53-3
Description: WV 760 is a biochemical.
Hodoodo Cat#: H581557
Name: WV 760
CAS#: 16809-53-3
Chemical Formula: C14H25ClNO2
Exact Mass: 274.16
Molecular Weight: 274.809
Elemental Analysis: C, 61.19; H, 9.17; Cl, 12.90; N, 5.10; O, 11.64
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: WV 760; Deacetylmoxisylyte hydrochloride; O-Deacetylmoxisylyte hydrochloride; WV760; WV-760
IUPAC/Chemical Name: 4-(beta-Dimethylaminoethoxy)carvacrol hydrochloride
InChi Key: OEYNATKPPBJVRU-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H24NO2.ClH/c1-11(2)14(17-9-8-15(4)5)7-6-12(3)13(16)10-14;/h6-7,10-11,16H,8-9H2,1-5H3;1H
SMILES Code: CC(C)C1(OCCN(C)C)=CC=C(C(O)=C1)C.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 274.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Marquer C, Bressolle F. Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence. Fundam Clin Pharmacol. 1998;12(4):377-87. Review. PubMed PMID: 9711459.
2: Marquer C, Bressolle F. High-performance liquid chromatographic determination of the conjugate metabolites of moxisylyte in human plasma and urine. J Chromatogr B Biomed Sci Appl. 1997 Apr 11;691(2):389-96. PubMed PMID: 9174276.
3: Marquer C, Trouvin JH, Lacolle JY, Dupont C, Jacquot C. Pharmacokinetics of a prodrug thymoxamine: dose-dependence of the metabolite ratio in healthy subjects. Eur J Drug Metab Pharmacokinet. 1991 Jul-Sep;16(3):183-8. PubMed PMID: 1839981.
4: Roquebert J, Malek A, Creuzet MH, Cognie F, Pontagnier H. Alpha 1- and alpha 2-adrenoceptor selectivity of moxisylyte (thymoxamine) and its metabolites in the pithed rat. Arch Int Pharmacodyn Ther. 1983 Dec;266(2):282-93. PubMed PMID: 6320755.